Status:
UNKNOWN
Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Dyslipidemias
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.
Eligibility Criteria
Inclusion
- Adults aged 19 years or over
- Patients with LDL-C levels ≤ 250 mg/dL, TG \< 500 mg/dL
- Subjects who voluntarily decided to participate and provided written consent after being told of the objectives, method, and effects of this study
Exclusion
- Severe congestive hear failure
- Current active liver disease
- The use of prohibiterd concomitant therapies
- Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding, active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is not controlled by medication, etc.
- Women who were of childbearing potential without contraception, pregnant, or breastfeeding
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT04772443
Start Date
February 1 2021
End Date
December 1 2022
Last Update
February 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.